^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:GZ17-6.02 (Apoptosis stimulant, Sonic hedgehog inhibitor, Stem cell inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Front Oncol
    Title:

    GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

    Published date:
    08/19/2021
    Excerpt:
    GZ17-6.02 interacted with the thymidylate synthase inhibitor pemetrexed to kill NSCLC cells expressing mutant ERBB1 proteins or mutant RAS proteins or cells that were resistant to EGFR inhibitors....GZ17-6.02 and pemetrexed interact to alter cell signaling, increase autophagosome formation, and kill via toxic autophagy A549 NSCLC cells that express a mutant K-RAS protein.
    Secondary therapy:
    pemetrexed
    DOI:
    https://doi.org/10.3389/fonc.2021.711043